Junshi Biosciences Takes Stake in Oncology JV via Asset Contribution

MT Newswires Live06-08

Shanghai Junshi Biosciences (HKG:1877, SHA:688180) plans to contribute intellectual property, pre-clinical research assets, and related technology rights to a newly formed oncology-focused joint venture, according to a Friday Hong Kong bourse filing.

In return, the biotech company will receive a 14.55% stake in the venture, Shanghai OnTarget Biopharmaceuticals.

The contributed assets were valued at about 53.1 million yuan, with the joint venture issuing 250,000 yuan of new registered capital to Junshi as consideration.

Junshi expects to record an unaudited gain of about 52.1 million yuan upon completion of the transaction.

The joint venture is developing multi-specific antibody and antibody-conjugate technologies for oncology treatments.

Hong Kong-listed shares of the firm were down more than 2% in Monday's late-morning trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641372103?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-08 12:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641372103","market":"nz","top_or_hot":-1,"title":"Junshi Biosciences Takes Stake in Oncology JV via Asset Contribution","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SHJBF\">Shanghai Junshi Biosciences</a> (HKG:1877, SHA:688180) plans to contribute intellectual property, pre-clinical research assets, and related technology rights to a newly formed oncology-focused joint venture, according to a Friday Hong Kong bourse filing.</p><p>In return, the biotech company will receive a 14.55% stake in the venture, Shanghai OnTarget Biopharmaceuticals.</p><p>The contributed assets were valued at about 53.1 million yuan, with the joint venture issuing 250,000 yuan of new registered capital to Junshi as consideration.</p><p>Junshi expects to record an unaudited gain of about 52.1 million yuan upon completion of the transaction.</p><p>The joint venture is developing multi-specific antibody and antibody-conjugate technologies for oncology treatments.</p><p>Hong Kong-listed shares of the firm were down more than 2% in Monday's late-morning trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Junshi Biosciences Takes Stake in Oncology JV via Asset Contribution</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJunshi Biosciences Takes Stake in Oncology JV via Asset Contribution\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-08 12:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SHJBF\">Shanghai Junshi Biosciences</a> (HKG:1877, SHA:688180) plans to contribute intellectual property, pre-clinical research assets, and related technology rights to a newly formed oncology-focused joint venture, according to a Friday Hong Kong bourse filing.</p><p>In return, the biotech company will receive a 14.55% stake in the venture, Shanghai OnTarget Biopharmaceuticals.</p><p>The contributed assets were valued at about 53.1 million yuan, with the joint venture issuing 250,000 yuan of new registered capital to Junshi as consideration.</p><p>Junshi expects to record an unaudited gain of about 52.1 million yuan upon completion of the transaction.</p><p>The joint venture is developing multi-specific antibody and antibody-conjugate technologies for oncology treatments.</p><p>Hong Kong-listed shares of the firm were down more than 2% in Monday's late-morning trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688180","symbol_name":"君实生物-U","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2641372103","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2641372103","pubTimestamp":1780891840,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Junshi Biosciences (HKG:1877, SHA:688180) plans to contribute intellectual property, pre-clinical research assets, and related technology rights to a newly formed oncology-focused joint ventu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688180":"君实生物-U","01877":"君实生物","BK0239":"医药制造","BK1161":"生物科技","BK1583":"高瓴概念","BK1515":"抗疫概念"},"translate_title":"君实生物通过资产出资入股肿瘤合资公司","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":0.9,"01877":0.9},"content_text":"Shanghai Junshi Biosciences (HKG:1877, SHA:688180) plans to contribute intellectual property, pre-clinical research assets, and related technology rights to a newly formed oncology-focused joint venture, according to a Friday Hong Kong bourse filing.In return, the biotech company will receive a 14.55% stake in the venture, Shanghai OnTarget Biopharmaceuticals.The contributed assets were valued at about 53.1 million yuan, with the joint venture issuing 250,000 yuan of new registered capital to Junshi as consideration.Junshi expects to record an unaudited gain of about 52.1 million yuan upon completion of the transaction.The joint venture is developing multi-specific antibody and antibody-conjugate technologies for oncology treatments.Hong Kong-listed shares of the firm were down more than 2% in Monday's late-morning trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641372103","isCrawlerRequest":true}